Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States

Expert Opinion on Pharmacotherapy
Michael K WongNicholas J Vogelzang

Abstract

Comparing prognostic factors for overall survival (OS) in community-practice metastatic renal cell carcinoma (mRCC) patients receiving second-line everolimus with those previously reported in clinical trials. Two separate chart sets (2009 - 2012) were used to develop and validate a prognostic model for patients initiating second-line everolimus after first-line tyrosine kinase inhibitor (TKI). Prognostic factors for OS have been identified and validated in separate samples. One-year OS probabilities in the study (n = 220) and validation (n = 97) samples were 68 and 67%; median OS was 19 and 23 months - higher than the 1-year OS of 60% and median OS of 14.8 months of RECORD-1. Karnofsky performance score < 80%, duration of mRCC < 1 year, progression on first-line TKI, liver metastasis and clear cell histology were significant prognostic factors for shorter survival. One-year OS estimates were 84% for validation sample patients with 0 - 2 risk factors, 63% for 3 risk factors and 22% for 4 - 5 risk factors (log-rank p < 0.001). Real-world prognostic factors for OS following second-line everolimus for mRCC were largely consistent with those previously identified in trial data; however, OS was longer in the practice setting than in ...Continue Reading

References

Mar 1, 1984·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C C SchagP A Ganz
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Jan 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Feb 5, 2004·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Andrew Worster, Ted Haines
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tarek M MekhailRonald Bukowski
Apr 9, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C N A M OldenhuisE G E de Vries
Feb 25, 2009·BMJ : British Medical Journal·Karel G M MoonsDouglas G Altman
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Jul 19, 2011·Hematology/oncology Clinics of North America·Patricia A TangDaniel Y C Heng
Aug 11, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Judith ManolaUNKNOWN International Kidney Cancer Working Group
Mar 1, 2012·Expert Review of Anticancer Therapy·Giuseppe Di LorenzoCarlo Buonerba
Mar 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christopher M Booth, Elizabeth A Eisenhauer
Mar 16, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Antonin LevyBernard Escudier
Mar 26, 2013·Critical Reviews in Oncology/hematology·Philippe BarthélémyBrigitte Duclos
Nov 13, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Anne V SoerensenPoul F Geertsen
Nov 28, 2013·Journal of Oncology Practice·Michael R HarrisonAmy P Abernethy
Jan 31, 2014·Medical Oncology·Maria StenmanMagnus Lindskog
Apr 22, 2014·Annals of Emergency Medicine·Amy H KajiSteven Green
Dec 17, 2014·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Sandhya R RaoWade J Sexton
Jan 24, 2015·International Braz J Urol : Official Journal of the Brazilian Society of Urology·Sandhya R RaoMurali K Ankem

❮ Previous
Next ❯

Citations

Oct 13, 2015·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·J D RebiboF-X Nouhaud
May 23, 2015·Expert Opinion on Pharmacotherapy·Carlo BuonerbaGiuseppe Di Lorenzo
Jan 21, 2017·Expert Review of Anticancer Therapy·José Luis González-LarribaUNKNOWN The Changing Group

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.